Advertisement
Online Images in the Medical Sciences| Volume 364, ISSUE 2, e26, August 2022

Varioliform-type lymphocytic gastritis: Treating H. pylori or (rather) something else?

  • Vincent Zimmer
    Correspondence
    Corresponding author at: Department of Medicine, Marienhausklinik St. Josef Kohlhof, Klinikweg 1-5, Neunkirchen 66539, Germany.
    Affiliations
    Department of Medicine, Marienhausklinik St. Josef Kohlhof, Neunkirchen, Germany

    Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
    Search for articles by this author
  • Kai Emrich
    Affiliations
    Insitute of Pathology Saarbrücken-Rastpfuhl, Saarbrücken, Germany
    Search for articles by this author
      A 71-year-old patient presented with dyspeptic complaints. Upper endoscopy indicated multiple small nodules with central depression in the gastric body and, to a much lesser extent, antrum (Fig. 1 A and B). Albeit the proximal stomach remained unremarkable without enlarged rugal folds, these findings were highly suggestive of varioliform gastritis (or octopus-sucker gastritis) reflective of lymphocytic gastritis (LG). Indeed, histopathology of targeted and systematic biopsies indicated prominent lymphoplasmacytic infiltration within the surface epithelium and gastric pits with intraepithelial lymphocytosis well >25/100 epithelial cells (Fig. 1 C, H&E, x10; inset CD8, x10). Overall, both endoscopy and histopathology indicated gastric body-predominant LP. Of note, histopathology including Giemsa staining and biochemical testing (urease, stool antigen) proved negative for Helicobacter pylori. Likewise, ancillary H pylori and celiac disease serology yielded unremarkable results. Nevertheless, the patient underwent “eradication” treatment using a conventional French triple treatment for 7 days. Albeit more effective eradication regimen and treatment durations have been established for H pylori eradication, we chose this regimen analogous to the only randomised trial for lymphocytic gastritis with high remission rates irrespective of H pylori status.
      • Madisch A
      • Miehlke S
      • Neuber F
      • et al.
      Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy–a randomized, double-blind, placebo-controlled multicentre trial.
      Following this, symptomatic, endoscopic and histopathological remission was documented (Fig. 1 D, H&E, x10).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Madisch A
        • Miehlke S
        • Neuber F
        • et al.
        Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy–a randomized, double-blind, placebo-controlled multicentre trial.
        Aliment Pharmacol Ther. 2006; 23: 473-479
        • Montalban-Arques A
        • Wurm P
        • Trajanoski S
        • et al.
        Propionibacterium acnes overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis.
        J Pathol. 2016; 240: 425-436